BackInhibikase Therapeutics Overview

Inhibikase Therapeutics Receivables

Inhibikase Therapeutics's receivables is $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer average

Loading

Inhibikase Therapeutics Receivables History

Loading

Inhibikase Therapeutics vs. peers: Receivables Comparison

Loading

Inhibikase Therapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Inhibikase Therapeutics (IKT) FAQ

As of the most recent data (March 2026), IKT shows a receivables of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, IKT's receivables is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Inhibikase Therapeutics is outperforming or lagging.

Tracking IKT's receivables over time shows whether Inhibikase Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Inhibikase Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $0) with ownership activity and broader fundamentals.

Inhibikase Therapeutics's receivables is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.